GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech

GSK's HSV Vaccine Failure:
GSK's experimental herpes simplex virus (HSV) vaccine, GSK3943104, failed to meet its primary efficacy goal in the phase I/II proof-of-concept study (TH HSV REC-003), leading to the discontinuation of its development.

Impact on HSV Vaccine Race:
The failure of GSK's HSV vaccine leaves the race open for other companies like Moderna and BioNTech, which are developing their own HSV vaccines using mRNA technology.

Moderna and BioNTech's Progress:
Moderna is advancing its mRNA-based HSV vaccine, mRNA-1608, in a Phase I/II study, while BioNTech's BNT163 is in its first-in-human Phase I trial.

GSK's Future Plans:
GSK will continue to collect safety and follow-up data from the TH HSV REC-003 study to inform future research and development in its HSV program.

GSK's Other Vaccine Developments:
GSK has reported encouraging results from a phase II trial of its mRNA-based seasonal influenza vaccine candidates and has restructured its collaboration with CureVac for mRNA vaccine development.